06:49 AM EDT, 09/26/2024 (MT Newswires) -- Axonics ( AXNX ) said Thursday that Australia's Therapeutic Goods Administration has approved the marketing of the company's R20 rechargeable sacral neuromodulation system as a treatment for adults suffering from overactive bladder and fecal incontinence.

The company said it expects to start sales of the R20 in Australia in November.